How to Personalize the Treatment in Patients With KRAS G12C, KRAS G12D, and KRAS G12V NSCLC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

How to Personalize the Treatment in Patients With KRAS G12C, KRAS G12D, and KRAS G12V NSCLC

By Biagio Ricciuti 8 Videos

480 views

November 3, 2022

This video was recorded prior to the FDA granting approval to adagrasib (Krazati) On December ...
read more ↘ 12, 2022.
↖ read less

0 Comments

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

The Use of IO Doublet in PD-L1-Negative NSCLC